Design, synthesis, biological evaluation and molecular docking of novel metronidazole derivatives as selective and potent JAK3 inhibitors

Design, synthesis, biological evaluation, and molecular modeling study of 4-alkoxyquinazoline derivatives as potential VEGFR2 kinase inhibitors

(2013) Jian Sun et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Tyrosine Kinase Inhibitors: Views of Selectivity, Sensitivity, and Clinical Performance

(2012) Alexander Levitzki   Annual Review of Pharmacology and Toxicology

How I treat polycythemia vera

(2012) F. Passamonti   BLOOD

Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells

(2012) Karolina Swiatek-Machado et al.   CANCER BIOLOGY & THERAPY

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metronidazole acid acyl sulfonamide: A novel class of anticancer agents and potential EGFR tyrosine kinase inhibitors

(2011) Yin Luo et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Synthesis and antitumor activity of 1,2,4-triazoles having 1,4-benzodioxan fragment as a novel class of potent methionine aminopeptidase type II inhibitors

(2011) Ya-Ping Hou et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Imidazole derivatives: A comprehensive survey of their recognition properties

(2011) Pedro Molina et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Antimitotic and Antiproliferative Activities of Chalcones: Forward Structure–Activity Relationship

(2008) Ahcène Boumendjel et al.   JOURNAL OF MEDICINAL CHEMISTRY